This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015):
* the evolution of oculomotricity markers over time. * the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years. * the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography. * the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.
Male or Female;
Clinically defined idiopathic Parkinson's Disease (PD);
Brain MRI performed in routine care in the 12 months preceding inclusion;
Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation;
Psychiatric comorbidity (except anxiety or mild to moderate depression);
Neurological comorbidity, if significant;
significant cerebrovascular pathology (Fazekas I admitted),
another brain disease, including stroke.
Association de Recherche Bibliographique pour les Neurosciences
Lead sponsor
Centre Hospitalier Princesse Grace
Collaborator
Centre Hospitalier Universitaire de Nice
Collaborator